Inhibitors | Comment | Organism | Structure |
---|---|---|---|
(2R)-N-hydroxy-2-(7-methoxy-1,1-dioxido-4,5-dihydro-1,2,5-benzothiadiazepin-2(3H)-yl)-3-methylbutanamide | - |
Sus scrofa | |
methyl (5R)-5-{7-[(3,5-diethoxybenzyl)oxy]-1,1-dioxido-4,5-dihydro-1,2,5-benzothiadiazepin-2(3H)-yl}-6-(hydroxyamino)-6-oxohexanoate | - |
Sus scrofa | |
methyl (5R)-5-{7-[(3,5-dimethoxybenzyl)oxy]-1,1-dioxido-4,5-dihydro-1,2,5-benzothiadiazepin-2(3H)-yl}-6-(hydroxyamino)-6-oxohexanoate | human whole blood assay: 31% inhibition | Sus scrofa | |
N-hydroxy-2(R)-(6-methoxy-1,1-dioxo-3,4-dihydro-1H-1-benzo[1,2,4]thiadiazin-2-yl)propionamide | - |
Sus scrofa | |
N-hydroxy-2(R)-[2,3,4,5-tetrahydrobenzo[1,2,5-f]-thiadiazepine-1,1-dioxide]propanamide | - |
Sus scrofa | |
N-hydroxy-2(R)-[7-(2,6-methylpyridyl-4-methyleneoxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]-propanamide | human whole blood assay: 37% inhibition | Sus scrofa | |
N-hydroxy-2(R)-[7-(2-trifluromethylphenyl)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]propylamide | - |
Sus scrofa | |
N-hydroxy-2(R)-[7-(3,5-dichlorobenzyloxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]propanamide | human whole blood assay: 12% inhibition | Sus scrofa | |
N-hydroxy-2(R)-[7-(3,5-diethoxybenzyloxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]-3-methylbutanamide | human whole blood assay: 17% inhibition | Sus scrofa | |
N-hydroxy-2(R)-[7-(3,5-diethoxybenzyloxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]-4-methoxycarbonylbutanamide | human whole blood assay: 0% inhibition | Sus scrofa | |
N-hydroxy-2(R)-[7-(3,5-diethoxybenzyloxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]propanamide | human whole blood assay: 26% inhibition | Sus scrofa | |
N-hydroxy-2(R)-[7-(3,5-dimethoxybenzyloxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine 1,1-dioxide]-6-N-(methanesulfonyl)hexylamide | - |
Sus scrofa | |
N-hydroxy-2(R)-[7-(3,5-dimethoxybenzyloxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]-3-methylbutanamide | human whole blood assay: 11% inhibition | Sus scrofa | |
N-hydroxy-2(R)-[7-(3,5-dimethoxybenzyloxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]-4-methoxycarbonylbutanamide | human whole blood assay: 0% inhibition | Sus scrofa | |
N-hydroxy-2(R)-[7-(3,5-dimethoxybenzyloxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]-4-methylpentanamide | human whole blood assay: 16% inhibition | Sus scrofa | |
N-hydroxy-2(R)-[7-(3,5-dimethoxybenzyloxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]-6-aminohexylamidetrifluoroacetic acid salt | human whole blood assay: 3% inhibition | Sus scrofa | |
N-hydroxy-2(R)-[7-(3,5-dimethoxybenzyloxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]-6-N-[(1,1-dimethylethoxy)carbonyl]hexylamide | human whole blood assay: 3% inhibition | Sus scrofa | |
N-hydroxy-2(R)-[7-(3,5-dimethoxybenzyloxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]propanamide | - |
Sus scrofa | |
N-hydroxy-2(R)-[7-(3,5-dimethylbenzyloxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]propanamide | human whole blood assay: 2% inhibition | Sus scrofa | |
N-hydroxy-2(R)-[7-(3-nitrophenoxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]propanamide | - |
Sus scrofa | |
N-hydroxy-2(R)-[7-(4,5-dimethylthiazolyl-2-methyleneoxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]-3-methylbutanamide | human whole blood assay: 0% inhibition | Sus scrofa | |
N-hydroxy-2(R)-[7-(4-methoxyphenoxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]propanamide | - |
Sus scrofa | |
N-hydroxy-2(R)-[7-(4-nitrophenoxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]propanamide | - |
Sus scrofa | |
N-hydroxy-2(R)-[7-(4-phenylphenoxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]propanamide | - |
Sus scrofa | |
N-hydroxy-2(R)-[7-(4-trifluoromethylphenoxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]propanamide | human whole blood assay: 58% inhibition | Sus scrofa | |
N-hydroxy-2(R)-[7-(N-3,5-dimethylbenzoylamino)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]-propylamide | - |
Sus scrofa | |
N-hydroxy-2(R)-[7-benzyloxy-2,3,4,5-tetrahydrobenzo-[1,2,5-f]thiadiazepine-1,1-dioxide]-4-methylpentanamide | human whole blood assay: 39% inhibition | Sus scrofa | |
N-hydroxy-2(R)-[7-benzyloxy-2,3,4,5-tetrahydrobenzo-[1,2,5-f]thiadiazepine-1,1-dioxide]propanamide | human whole blood assay: 30% inhibition | Sus scrofa | |
N-hydroxy-2(R)-[7-hydroxy-2,3,4,5-tetrahydrobenzo-[1,2,5-f]thiadiazepine-1,1-dioxide]-4-methylpentamide | human whole blood assay: 20% inhibition | Sus scrofa | |
N-hydroxy-2(R)-[7-hydroxy-2,3,4,5-tetrahydrobenzo-[1,2,5-f]thiadiazepine-1,1-dioxide]propanamide | human whole blood assay: 21% inhibition | Sus scrofa | |
N-hydroxy-2(R)-[7-methoxy-2,3,4,5-tetrahydrobenzo-[1,2,5-f]thiadiazepine-1,1-dioxide]propanamide | - |
Sus scrofa | |
N-hydroxy-2(R)-[7-N-(3,5-dimethoxymethyleneamino)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]-4-methylpentamide | human whole blood assay: 3% inhibition | Sus scrofa | |
N-hydroxy-2(R)-[7-phenoxy-2,3,4,5-tetrahydrobenzo-[1,2,5-f]thiadiazepine-1,1-dioxide]propanamide | - |
Sus scrofa | |
N-hydroxy-2(R)-[7-phenyl-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]propylamide | - |
Sus scrofa | |
N-hydroxy-2-[2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]ethanamide | - |
Sus scrofa | |
N-hydroxy-2-[7-methoxy-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]ethanamide | - |
Sus scrofa |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Sus scrofa | - |
- |
- |
Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|
additional information | compounds are assessed in two cellular assays, the human peripheral blood mononuclear cell assay (PBMC) and the human whole blood assay (WBA), for their ability to suppress the formation of TNF-alpha brought about by lipopolysaccharide (LPS) stimulation. Success in the PBMC assay relies on the ability of the inhibitor to penetrate into the cells, thus enabling it to inhibit TACE and thereby to suppress the release of intracellular, soluble TNF-alpha. In the WBA, compounds must also have the ability to penetrate cells | Sus scrofa | ? | - |
? |
Synonyms | Comment | Organism |
---|---|---|
TACE | - |
Sus scrofa |
Ki Value [mM] | Ki Value maximum [mM] | Inhibitor | Comment | Organism | Structure |
---|---|---|---|---|---|
0.000005 | - |
N-hydroxy-2(R)-[7-(3,5-dimethoxybenzyloxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine 1,1-dioxide]-6-N-(methanesulfonyl)hexylamide | - |
Sus scrofa | |
0.00001 | - |
N-hydroxy-2(R)-[7-(3,5-dimethoxybenzyloxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]-3-methylbutanamide | - |
Sus scrofa | |
0.00001 | - |
methyl (5R)-5-{7-[(3,5-dimethoxybenzyl)oxy]-1,1-dioxido-4,5-dihydro-1,2,5-benzothiadiazepin-2(3H)-yl}-6-(hydroxyamino)-6-oxohexanoate | - |
Sus scrofa | |
0.000011 | - |
N-hydroxy-2(R)-[7-(4-nitrophenoxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]propanamide | - |
Sus scrofa | |
0.000013 | - |
methyl (5R)-5-{7-[(3,5-diethoxybenzyl)oxy]-1,1-dioxido-4,5-dihydro-1,2,5-benzothiadiazepin-2(3H)-yl}-6-(hydroxyamino)-6-oxohexanoate | - |
Sus scrofa | |
0.000017 | - |
N-hydroxy-2(R)-[7-(3,5-dimethoxybenzyloxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]-4-methylpentanamide | - |
Sus scrofa | |
0.000027 | - |
N-hydroxy-2(R)-[7-(3,5-dimethoxybenzyloxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]propanamide | - |
Sus scrofa | |
0.000031 | - |
N-hydroxy-2(R)-[7-(3,5-dimethoxybenzyloxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]-6-aminohexylamidetrifluoroacetic acid salt | - |
Sus scrofa | |
0.000051 | - |
N-hydroxy-2(R)-[7-(3,5-diethoxybenzyloxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]-3-methylbutanamide | - |
Sus scrofa | |
0.000056 | - |
N-hydroxy-2(R)-[7-N-(3,5-dimethoxymethyleneamino)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]-4-methylpentamide | - |
Sus scrofa | |
0.000071 | - |
(2R)-N-hydroxy-2-(7-methoxy-1,1-dioxido-4,5-dihydro-1,2,5-benzothiadiazepin-2(3H)-yl)-3-methylbutanamide | - |
Sus scrofa | |
0.000077 | - |
N-hydroxy-2(R)-[7-(3,5-dimethoxybenzyloxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]-6-N-[(1,1-dimethylethoxy)carbonyl]hexylamide | - |
Sus scrofa | |
0.000081 | - |
N-hydroxy-2(R)-[7-(3,5-diethoxybenzyloxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]propanamide | - |
Sus scrofa | |
0.000089 | - |
N-hydroxy-2(R)-[7-hydroxy-2,3,4,5-tetrahydrobenzo-[1,2,5-f]thiadiazepine-1,1-dioxide]-4-methylpentamide | - |
Sus scrofa | |
0.000129 | - |
N-hydroxy-2(R)-[7-(3-nitrophenoxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]propanamide | - |
Sus scrofa | |
0.000153 | - |
N-hydroxy-2(R)-[7-(3,5-dichlorobenzyloxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]propanamide | - |
Sus scrofa | |
0.000177 | - |
N-hydroxy-2(R)-[7-benzyloxy-2,3,4,5-tetrahydrobenzo-[1,2,5-f]thiadiazepine-1,1-dioxide]-4-methylpentanamide | - |
Sus scrofa | |
0.000177 | - |
N-hydroxy-2(R)-[7-(3,5-dimethoxybenzyloxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]-4-methoxycarbonylbutanamide | - |
Sus scrofa | |
0.000229 | - |
N-hydroxy-2(R)-[7-(3,5-dimethylbenzyloxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]propanamide | - |
Sus scrofa | |
0.000242 | - |
N-hydroxy-2(R)-[7-(3,5-diethoxybenzyloxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]-4-methoxycarbonylbutanamide | - |
Sus scrofa | |
0.000274 | - |
N-hydroxy-2(R)-[7-methoxy-2,3,4,5-tetrahydrobenzo-[1,2,5-f]thiadiazepine-1,1-dioxide]propanamide | - |
Sus scrofa | |
0.00029 | - |
N-hydroxy-2(R)-[7-(4,5-dimethylthiazolyl-2-methyleneoxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]-3-methylbutanamide | - |
Sus scrofa | |
0.000391 | - |
N-hydroxy-2(R)-[7-hydroxy-2,3,4,5-tetrahydrobenzo-[1,2,5-f]thiadiazepine-1,1-dioxide]propanamide | - |
Sus scrofa | |
0.000484 | - |
N-hydroxy-2(R)-[2,3,4,5-tetrahydrobenzo[1,2,5-f]-thiadiazepine-1,1-dioxide]propanamide | - |
Sus scrofa | |
0.000544 | - |
N-hydroxy-2(R)-[7-(2,6-methylpyridyl-4-methyleneoxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]-propanamide | - |
Sus scrofa | |
0.000621 | - |
N-hydroxy-2(R)-[7-(4-methoxyphenoxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]propanamide | - |
Sus scrofa | |
0.000705 | - |
N-hydroxy-2(R)-[7-benzyloxy-2,3,4,5-tetrahydrobenzo-[1,2,5-f]thiadiazepine-1,1-dioxide]propanamide | - |
Sus scrofa | |
0.000734 | - |
N-hydroxy-2(R)-[7-phenoxy-2,3,4,5-tetrahydrobenzo-[1,2,5-f]thiadiazepine-1,1-dioxide]propanamide | - |
Sus scrofa | |
0.000758 | - |
N-hydroxy-2(R)-[7-(4-trifluoromethylphenoxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]propanamide | - |
Sus scrofa | |
0.001 | - |
N-hydroxy-2-[2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]ethanamide | - |
Sus scrofa | |
0.001 | - |
N-hydroxy-2-[7-methoxy-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]ethanamide | - |
Sus scrofa | |
0.001 | - |
N-hydroxy-2(R)-[7-(N-3,5-dimethylbenzoylamino)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]-propylamide | value above | Sus scrofa | |
0.001 | - |
N-hydroxy-2(R)-[7-phenyl-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]propylamide | value above | Sus scrofa | |
0.001 | - |
N-hydroxy-2(R)-[7-(2-trifluromethylphenyl)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]propylamide | value above | Sus scrofa | |
0.001 | - |
N-hydroxy-2(R)-[7-(4-phenylphenoxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]propanamide | value above | Sus scrofa | |
0.0031 | - |
N-hydroxy-2(R)-(6-methoxy-1,1-dioxo-3,4-dihydro-1H-1-benzo[1,2,4]thiadiazin-2-yl)propionamide | - |
Sus scrofa |
IC50 Value | IC50 Value Maximum | Comment | Organism | Inhibitor | Structure |
---|---|---|---|---|---|
0.00035 | - |
human peripheral blood mononuclear cell assay (PBMC) | Sus scrofa | N-hydroxy-2(R)-[7-benzyloxy-2,3,4,5-tetrahydrobenzo-[1,2,5-f]thiadiazepine-1,1-dioxide]-4-methylpentanamide | |
0.00047 | - |
human peripheral blood mononuclear cell assay (PBMC) | Sus scrofa | N-hydroxy-2(R)-[7-(3-nitrophenoxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]propanamide | |
0.00077 | - |
human peripheral blood mononuclear cell assay (PBMC) | Sus scrofa | N-hydroxy-2(R)-[7-(3,5-dimethoxybenzyloxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]propanamide | |
0.00084 | - |
human peripheral blood mononuclear cell assay (PBMC) | Sus scrofa | N-hydroxy-2(R)-[7-(4-trifluoromethylphenoxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]propanamide | |
0.0009 | - |
human peripheral blood mononuclear cell assay (PBMC) | Sus scrofa | methyl (5R)-5-{7-[(3,5-dimethoxybenzyl)oxy]-1,1-dioxido-4,5-dihydro-1,2,5-benzothiadiazepin-2(3H)-yl}-6-(hydroxyamino)-6-oxohexanoate | |
0.00094 | - |
human peripheral blood mononuclear cell assay (PBMC) | Sus scrofa | N-hydroxy-2(R)-[7-(3,5-dichlorobenzyloxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]propanamide | |
0.0011 | - |
human peripheral blood mononuclear cell assay (PBMC) | Sus scrofa | methyl (5R)-5-{7-[(3,5-diethoxybenzyl)oxy]-1,1-dioxido-4,5-dihydro-1,2,5-benzothiadiazepin-2(3H)-yl}-6-(hydroxyamino)-6-oxohexanoate | |
0.0012 | - |
human peripheral blood mononuclear cell assay (PBMC) | Sus scrofa | N-hydroxy-2(R)-[7-(4-nitrophenoxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]propanamide | |
0.0019 | - |
human peripheral blood mononuclear cell assay (PBMC) | Sus scrofa | N-hydroxy-2(R)-[7-(3,5-dimethoxybenzyloxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine 1,1-dioxide]-6-N-(methanesulfonyl)hexylamide | |
0.0029 | - |
human peripheral blood mononuclear cell assay (PBMC) | Sus scrofa | N-hydroxy-2(R)-[7-(2,6-methylpyridyl-4-methyleneoxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]-propanamide | |
0.004 | - |
human peripheral blood mononuclear cell assay (PBMC) | Sus scrofa | N-hydroxy-2(R)-[7-(3,5-dimethoxybenzyloxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]-3-methylbutanamide | |
0.0045 | - |
human peripheral blood mononuclear cell assay (PBMC) | Sus scrofa | N-hydroxy-2(R)-[7-(3,5-diethoxybenzyloxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]propanamide | |
0.0054 | - |
human peripheral blood mononuclear cell assay (PBMC) | Sus scrofa | N-hydroxy-2(R)-[7-(3,5-dimethoxybenzyloxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]-4-methylpentanamide | |
0.0062 | - |
human peripheral blood mononuclear cell assay (PBMC) | Sus scrofa | N-hydroxy-2(R)-[7-(3,5-diethoxybenzyloxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]-4-methoxycarbonylbutanamide | |
0.0072 | - |
human peripheral blood mononuclear cell assay (PBMC) | Sus scrofa | N-hydroxy-2(R)-[7-(3,5-dimethoxybenzyloxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]-4-methoxycarbonylbutanamide | |
0.0082 | - |
human peripheral blood mononuclear cell assay (PBMC) | Sus scrofa | N-hydroxy-2(R)-[7-(3,5-diethoxybenzyloxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]-3-methylbutanamide | |
0.0095 | - |
human peripheral blood mononuclear cell assay (PBMC) | Sus scrofa | N-hydroxy-2(R)-[7-hydroxy-2,3,4,5-tetrahydrobenzo-[1,2,5-f]thiadiazepine-1,1-dioxide]-4-methylpentamide | |
0.0245 | - |
human peripheral blood mononuclear cell assay (PBMC) | Sus scrofa | N-hydroxy-2(R)-[7-(4,5-dimethylthiazolyl-2-methyleneoxy)-2,3,4,5-tetrahydrobenzo[1,2,5-f]thiadiazepine-1,1-dioxide]-3-methylbutanamide |